1. Home
  2. PETZ vs SCLX Comparison

PETZ vs SCLX Comparison

Compare PETZ & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TDH Holdings Inc.

PETZ

TDH Holdings Inc.

N/A

Current Price

$1.14

Market Cap

11.3M

Sector

Industrials

ML Signal

N/A

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$1.26

Market Cap

12.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PETZ
SCLX
Founded
2002
2011
Country
China
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.3M
12.0M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
PETZ
SCLX
Price
$1.14
$1.26
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.6K
★ 34.4K
Earning Date
11-27-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $30,253,000.00
Revenue This Year
N/A
$118.16
Revenue Next Year
N/A
$186.31
P/E Ratio
$6.89
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.81
$1.40
52 Week High
$1.83
$27.00

Technical Indicators

Market Signals
Indicator
PETZ
SCLX
Relative Strength Index (RSI) 51.17 11.57
Support Level $1.11 N/A
Resistance Level $1.37 $7.77
Average True Range (ATR) 0.06 0.15
MACD -0.00 0.04
Stochastic Oscillator 63.83 0.00

Price Performance

Historical Comparison
PETZ
SCLX

About PETZ TDH Holdings Inc.

TDH Holdings Inc currently focus on commercial real estate management. The company has determined that it has only one operating segment which is commercial real estate leasing operations. The company has presence in China and United States of which majority of revenue comes from China.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: